Novel Drug Regimen Can Improve Stem Cell Transplantation Outcomes – RedOrbit
|
Novel Drug Regimen Can Improve Stem Cell Transplantation Outcomes
RedOrbit Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem–cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber … |
